This session will provide late-breaking information on leading clinical trials affecting the pulmonary, critical care and sleep community.
CME credits and/or Certificates of Completion are not provided for this session.
1- Learn new findings from recent clinical trials that can be integrated in treatment options for patients with pulmonary disease
2- Learn new findings about emerging biologic therapies for moderate and severe asthma in adult and pediatric subjects
3- Learn new findings about opportunities for outpatient use of monoclonal antibody therapy to treat SARS Co-V2 infection and reduce risk for Critical Care
Jeanine M. D'Armiento, MD, PhD: Welcome and Introduction
Leonard B. Bacharier, MD: Efficacy and Safety of Dupilumab in Children 6 to 11 Years of Age with Uncontrolled Moderate-to-Severe Asthma
Julie Philley, MD: Casirivimab with Imdevimab, a Cocktail of Two Antibodies Against SARS-CoV-2, in the Outpatient Setting: Phase 3 Efficacy and Safety Results
Michael E. Wechsler, MD, MSc: Latest Clinical Evidence from Phase 3 Tezepelumab Trials in Severe Asthma
Jennifer L. Taylor-Cousar, MD, MSc, ATSF : Closing Remarks
You can save 20% today by joining the ATS. Join more than 16,000 healthcare providers and researchers as a member of the American Thoracic Society today. As an ATS member, you’ll gain access to cutting-edge science, collaboration opportunities, discounts on the annual ATS International Conference, and resources to share with patients. The ATS offers multiple ways to get involved, from Assembly membership to in-person networking opportunities, as well as an online community offered through DocMatter. Join the ATS Today!